Lei Li

Dr. Lei Li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Small
Verified
Journal Article
Closed access
PDF file
YLYangyang Li
Yangyang Li
WCWeiyu Chen
Weiyu Chen
YQYuchen Qi
Yuchen Qi
SWShuai Wang
Shuai Wang
LLLei Li
Lei Li
MZMin Zhou
Min Zhou

11 September 2019 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
LZLei Zhou
Lei Zhou
LYLiangfang Yao
Liangfang Yao
QZQing Zhang
Qing Zhang
WXWei Xie
Wei Xie
XWXiaoshuang Wang
Xiaoshuang Wang
HLHenry (Xiaotao) James Li
Henry (Xiaotao) James Li

21 April 2024 in Cancer Letters
Verified
Journal Article
Closed access
ZLZhi Li
Zhi Li
QXQi Xia
Qi Xia
YHYujie He
Yujie He
LLLei Li
Lei Li
PYPeihao Yin
Peihao Yin

26 June 2019 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
FDFatima Zohra Dahmani
Fatima Zohra Dahmani
DZDanni Zhong
Danni Zhong
YQYuchen Qi
Yuchen Qi
ADAboubaker El G. Dahmani
Aboubaker El G. Dahmani
TXTingting Xie
Tingting Xie
MZMin Zhou
Min Zhou
Nowadays, the design of multistimuli-responsive and deep penetrating nanotherapeutics remains an auspicious means for improving the efficiency of anticancer therapeutics. Herein, we develop a targeted size-tunable nanosystem that would concurrently and uniformly release its therapeutic cargo into tumor cells by exploiting both extracellular and intracellular signals. This nanosystem (HPDAu) is composed of self-assembled pH-responsive DOX–PAMAM (PD) conjugates and ultrasmall PAMAM-stabilized gold nanoparticles (AuNPs), incorporated into a hyaluronidase-responsive hyaluronic acid nanoshell. HPDAu nanoparticles with an initial particle size of ∼100 nm could disassemble into tiny cationic nanostructures (∼5 nm, PD and AuNPs) upon incubation with HAase, and showed a burst drug-release under tumor microenvironment-mimicking conditions (HAase and acidic conditions). Such characteristics resulted in significantly improved tumor penetration both in vitro and in vivo, along with a higher cellular uptake efficiency and tumor accumulation as compared to free drug solutions. Taking advantage of these features along with the chemotherapeutic effect (DOX) and AuNP/DOX-induced radiosensitization, HPDAu plus radiotherapy (RT) treatment resulted in a substantial increase of apoptotic and cytotoxic effects against 4T1 cells. More importantly, the radio-/chemotherapeutic feasibility of HPDAu was further validated in a 4T1 orthotropic model, revealing a prominent antitumor efficacy and reduced side-toxicity compared to monotherapy and free drug solutions. Therefore, this versatile nanoplatform with active targeting, size tunability and radio-/chemotherapeutic features could be a promising tool for tumor combinatorial therapy.

4 February 2026 in Advanced Science
Verified
Journal Article
Open access
YDYi Ding
Yi Ding
YTYuying Tian
Yuying Tian
WRWenjie Ren
Wenjie Ren
XHXianglin Hu
Xianglin Hu
MLMengjuan Li
Mengjuan Li
KLKun Li
Kun Li
Bone metastasis is a devastating consequence of lung cancer. However, the key metabolic factors that determine the risk of bone metastasis remain unclear. Here, we show that glucose transporter type 3 (SLC2A3) is notably overexpressed by lung cancer bone metastatic cells and tissues, as a facilitator of lung cancer bone metastasis. Additionally, SLC2A3 promotes glucose metabolism, which promotes tumor cell proliferation and metastasis via lactate‐mediated p53 lactylation. Within the tumor microenvironment, cancer cells serve as the primary source of secreted lactate, which induces protumor bone metastasis via osteoclast differentiation and suppresses the antitumor activity of CD8 + T cells. Subsequently, we developed Paris saponin VII, a SLC2A3 inhibitor that effectively suppressed bone metastasis in lung cancer bone metastasis mouse models and patient organoids. Notably, either inhibition of SLC2A3 or lactate limitation improved the tumor response and increased the sensitivity of lung cancer bone metastases to PD‐1 treatment. Collectively, our findings highlight that targeting SLC2A3‐mediated lactate metabolism, either alone or in combination with PD‐1 inhibition, is a potential strategy for treating lung cancer bone metastasis.

13 November 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YDYingying Du
Yingying Du
HCHui Chen
Hui Chen
LZLei Zhou
Lei Zhou
QGQunfeng Guo
Qunfeng Guo
SGShuangming Gong
Shuangming Gong
LLLei Li
Lei Li
Primary osteoporosis, manifesting as decreased bone mass and increased bone fragility, is a “silent disease” that is often ignored until a bone breaks. Accordingly, it is urgent to develop reliable biomarkers and novel therapeutic strategies for osteoporosis treatment. Here, we identified REGγ as a potential biomarker of osteoporotic populations through proteomics analysis. Next, we demonstrated that REGγ deficiency increased osteoclast activity and triggered bone mass loss in REGγ knockout (KO) and bone marrow-derive macrophage (BMM)-conditional REGγ KO mice. However, the osteoclast activity decreased in BMM-conditional REGγ overexpression mice. Mechanistically, we defined that REGγ-20S proteasome directly degraded TRAF6 to inhibit bone absorption in a ubiquitin-independent pathway. More importantly, BMM-conditional Traf6 KO with REGγ KO mice could “rescue” the osteoporosis phenotypes. Based on NIP30 (a REGγ “inhibitor”) dephosphorylation by CKII inhibition activated the ubiquitin-independent degradation of TRAF6, we selected TTP22, an inhibitor of CKII, and defined that TTP22 could alleviate osteoporosis in vitro and in vivo. Overall, our study reveals a unique function of NIP30/REGγ/TRAF6 axis in osteoporosis and provides a potential therapeutic drug TTP22 for osteoporosis.